Evidence map›Paper›PMID 35579096›Full record

Trial reportProteomics. Clinical applications2022

Proteomics reveals unique plasma signatures in constitutional thinness.

Ornella Cominetti, Antonio Núñez Galindo, John Corthésy, Jérôme Carayol, Natacha Germain, Bogdan Galusca, Bruno Estour, Jörg Hager, Nele Gheldof, Loïc Dayon

Registry-linked trialOpen access · hybridAbstract readClinical Trial
In one paragraph

Trial report in Proteomics. Clinical applications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02004821 (Génomique de la résistance à la Prise de Poids Dans la Maigreur Constitutionnelle), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02004821 nacompletednot on this map

Génomique de la résistance à la Prise de Poids Dans la Maigreur Constitutionnelle

TypeinterventionalSponsorSociété des Produits Nestlé (SPN)Ran2013 to 2016Enrolled60ConditionsIndividuals With Constitutional ThinnessArmsRenutryl® Booster, an oral nutritional supplement in a 300 ml bottle (600 kcal, 30 g protein, 72 g carbohydrate, 21 g fat). One bottle per day during 14 days.
3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Trial
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Ornella CominettiNestlé Institute of Food Safety & Analytical Sciences, Nestlé Research, Lausanne, Switzerland.ORCID 0000-0001-8564-1963
Antonio Núñez GalindoNestlé Institute of Food Safety & Analytical Sciences, Nestlé Research, Lausanne, Switzerland.ORCID 0000-0003-2619-4475
John CorthésyNestlé Institute of Food Safety & Analytical Sciences, Nestlé Research, Lausanne, Switzerland.
Jérôme CarayolNestlé Institute of Health Sciences, Nestlé Research, Lausanne, Switzerland.ORCID 0000-0002-0049-0244
Natacha GermainDivision of Endocrinology, Diabetes, Metabolism and Eating Disorders, CHU St-Etienne, France.
Bogdan GaluscaDivision of Endocrinology, Diabetes, Metabolism and Eating Disorders, CHU St-Etienne, France.ORCID 0000-0002-0154-6924
Bruno EstourDivision of Endocrinology, Diabetes, Metabolism and Eating Disorders, CHU St-Etienne, France.
Jörg HagerNestlé Institute of Health Sciences, Nestlé Research, Lausanne, Switzerland.
Nele GheldofNestlé Institute of Health Sciences, Nestlé Research, Lausanne, Switzerland.ORCID 0000-0001-8922-7372
Loïc DayonNestlé Institute of Food Safety & Analytical Sciences, Nestlé Research, Lausanne, Switzerland.ORCID 0000-0002-8499-270X
Nestlé (Switzerland) · CHCentre Hospitalier Universitaire de Saint-Étienne · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeStudying the plasma proteome of control versus constitutionally thin (CT) individuals, exposed to overfeeding, may give insights into weight-gain management, providing relevant information to the clinical entity of weight-gain resistant CT, and discovering new markers for the condition. EXPERIMENTAL

designUntargeted protein relative quantification of 63 CT and normal-weight individuals was obtained in blood plasma at baseline, during and after an overfeeding challenge using mass spectrometry-based proteomics.

resultsThe plasma proteome of CT subjects presented limited specificity with respect to controls at baseline. Yet, CT showed lower levels of inflammatory C-reactive protein and larger levels of protective insulin-like growth factor-binding protein 2. Differences were more marked during and after overfeeding. CT plasma proteome showed larger magnitude and significance in response, suggesting enhanced "resilience" and more rapid adaptation to changes. Four proteins behaved similarly between CT and controls, while five were regulated in opposite fashion. Ten proteins were differential during overfeeding in CT only (including increased fatty acid-binding protein and glyceraldehyde-3-phosphate dehydrogenase, and decreased apolipoprotein C-II and transferrin receptor protein 1). CONCLUSIONS AND CLINICAL RELEVANCE: This first proteomic profiling of a CT cohort reveals different plasma proteomes between CT subjects and controls in a longitudinal clinical trial. Our molecular observations further support that the resistance to weight gain in CT subjects appears predominantly biological. CLINICALTRIALS: gov Identifier: NCT02004821.

Indexed as

ProteomicsSomatomedinsC-Reactive ProteinFatty Acid-Binding ProteinsHumansPlasmaProteomeReceptors, TransferrinThinnessC-Reactive ProteinFatty Acid-Binding ProteinsProteomeReceptors, TransferrinSomatomedinsconstitutional thinnessisobaric taggingmass spectrometryoverfeeding challengeshotgun proteomics

Identifiers

PMID35579096
PMCPMC9787820
OpenAlexW4280510935

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.